Ben Carpenter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ben Carpenter has a total of 239 co-authors. Here are the top co-authors by number of shared publications:
Eleni Tholouli
19Department of Haematology, Manchester Royal Infirmary, Manchester, United Kingdom
3 shared publications- Emma Nicholson
The Royal Marsden NHS Foundation Trust, London, United Kingdom
3 shared publications - John A. Snowden
Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
3 shared publications Rachael Hough
Department of Haematology, University College London Hospitals National Hospital Service Foundation Trust, London, United Kingdom
3 shared publicationsVictoria Potter
Department of Haematological Medicine, King's College Hospital NHS, London, UK
3 shared publications- Adrian Bloor
Haematology & Transplant Unit, The Christie NHS Foundation Trust, Manchester, UK
2 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (6)
Characterization of a novel homozygous CTLA4 variant
Cytotoxic T lymphocyte–associated antigen-4 (CTLA4) is an inhibitory co-receptor. We report a homozygous variant in CTLA4 residing in the 3′UTR of the CTLA4 gene. The patient was deficient in peripheral blood T regulatory cells that was partially reversed with abatacept.
- 21 October 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (6)
Open AccessCharacterization of a novel homozygous CTLA4 variant
Cytotoxic T lymphocyte–associated antigen-4 (CTLA4) is an inhibitory co-receptor. We report a homozygous variant in CTLA4 residing in the 3′UTR of the CTLA4 gene. The patient was deficient in peripheral blood T regulatory cells that was partially reversed with abatacept.
- Open Access
A Pilot Project to Evaluate the Benefit of Additional Support in Haematopoietic Cell Transplant (HCT) Research Data Management on Behalf of Anthony Nolan and BSBMTCT
Background: The participation of transplant centres in research studies that request detailed follow‐up data on included patients can be challenging due to the amount of time centre Data Managers have to complete additional requests. The Research Data Manager (RDM) Pilot Project was designed to support Anthony Nolan's longitudinal Patient/Donor project and provide real‐world evidence of the benefit of additional and dedicated data management resources in transplant centres. Objectives: For Anthony Nolan to continue advancing the field of donor selection, up‐to‐date and accurate follow‐up data is needed. This 12‐month pilot project aimed to demonstrate how on‐the‐ground support could improve access to outcome data. Study Design: Following RDM placements at two participating centres, we reviewed the data quality and quantity collected, thus ensuring the methods used remain effective and are likely to result in successful and continuous data improvement. The cohort covered a broad timespan and included historical patient records, posing challenges in availability of prior data and long‐term follow‐up of discharged patients. Results: Following the placements, over 400 patients now have the most up‐to‐date and complete patient clinical outcome data available within the EBMT/BSBMTCT registry database for any group to study, reducing the burden on these centres to complete research data requests for these individuals. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission
Open AccessA Pilot Project to Evaluate the Benefit of Additional Support in Haematopoietic Cell Transplant (HCT) Research Data Management on Behalf of Anthony Nolan and BSBMTCT
Background: The participation of transplant centres in research studies that request detailed follow‐up data on included patients can be challenging due to the amount of time centre Data Managers have to complete additional requests. The Research Data Manager (RDM) Pilot Project was designed to support Anthony Nolan's longitudinal Patient/Donor project and provide real‐world evidence of the benefit of additional and dedicated data management resources in transplant centres. Objectives: For Anthony Nolan to continue advancing the field of donor selection, up‐to‐date and accurate follow‐up data is needed. This 12‐month pilot project aimed to demonstrate how on‐the‐ground support could improve access to outcome data. Study Design: Following RDM placements at two participating centres, we reviewed the data quality and quantity collected, thus ensuring the methods used remain effective and are likely to result in successful and continuous data improvement. The cohort covered a broad timespan and included historical patient records, posing challenges in availability of prior data and long‐term follow‐up of discharged patients. Results: Following the placements, over 400 patients now have the most up‐to‐date and complete patient clinical outcome data available within the EBMT/BSBMTCT registry database for any group to study, reducing the burden on these centres to complete research data requests for these individuals. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission
- Open Access
- 12 December 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (24) , 6502-6510
Improvements in health-related quality of life in patients with transfusion-dependent β-thalassemia after exagamglogene autotemcel
Transfusion-dependent β-thalassemia (TDT) can have negative impacts on a patient’s health-related quality of life (HRQoL). Exagamglogene autotemcel (exa-cel) is a one-time, ex vivo CRISPR-Cas9 gene–edited cell therapy for TDT shown in a phase 3 clinical trial to result in transfusion independence in most participants. Here, we describe changes in patient-reported outcome (PRO) measures after exa-cel infusion in 54 participants (adults, n = 35; adolescents, n = 19), who had ≥16 months of follow-up. In adults, PRO measures included the EuroQol Quality of Life Scale-5 dimensions-5 levels of severity (EQ-5D-5L) and the Functional Assessment of Cancer Therapy Bone Marrow Transplant (FACT-BMT). In adolescents, the EuroQol Quality of Life Scale-5 dimensions-youth (EQ-5D-Y) and Pediatric Quality of Life Inventory (PedsQL) instruments were used. At baseline, mean EQ-5D-5L visual analog scale (VAS) and US and UK health utility index scores in adults were in line with baseline scores reported for adults with TDT. After exa-cel infusion, all 3 scores improved, exceeding established minimal clinically important differences (MCIDs) at month 48. Mean FACT-General (FACT-G) score and bone marrow transplant subscale score improved through month 48, also exceeding MCIDs, with improvements in all 4 FACT-G subscales (physical, social/family, emotional, and functional well-being). Consistent with HRQoL improvements in adults, adolescents had increases from baseline at month 24 in mean EQ-5D-Y VAS score and PedsQL total score, with sustained improvements in both physical and psychosocial health subcomponents. These results indicate exa-cel leads to broad, durable, and clinically meaningful improvements in HRQoL in adults and adolescents with TDT. These trials were registered at www.ClinicalTrials.gov as #NCT03655678 and #NCT04208529.
- 12 December 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (24) , 6502-6510
Open AccessImprovements in health-related quality of life in patients with transfusion-dependent β-thalassemia after exagamglogene autotemcel
Transfusion-dependent β-thalassemia (TDT) can have negative impacts on a patient’s health-related quality of life (HRQoL). Exagamglogene autotemcel (exa-cel) is a one-time, ex vivo CRISPR-Cas9 gene–edited cell therapy for TDT shown in a phase 3 clinical trial to result in transfusion independence in most participants. Here, we describe changes in patient-reported outcome (PRO) measures after exa-cel infusion in 54 participants (adults, n = 35; adolescents, n = 19), who had ≥16 months of follow-up. In adults, PRO measures included the EuroQol Quality of Life Scale-5 dimensions-5 levels of severity (EQ-5D-5L) and the Functional Assessment of Cancer Therapy Bone Marrow Transplant (FACT-BMT). In adolescents, the EuroQol Quality of Life Scale-5 dimensions-youth (EQ-5D-Y) and Pediatric Quality of Life Inventory (PedsQL) instruments were used. At baseline, mean EQ-5D-5L visual analog scale (VAS) and US and UK health utility index scores in adults were in line with baseline scores reported for adults with TDT. After exa-cel infusion, all 3 scores improved, exceeding established minimal clinically important differences (MCIDs) at month 48. Mean FACT-General (FACT-G) score and bone marrow transplant subscale score improved through month 48, also exceeding MCIDs, with improvements in all 4 FACT-G subscales (physical, social/family, emotional, and functional well-being). Consistent with HRQoL improvements in adults, adolescents had increases from baseline at month 24 in mean EQ-5D-Y VAS score and PedsQL total score, with sustained improvements in both physical and psychosocial health subcomponents. These results indicate exa-cel leads to broad, durable, and clinically meaningful improvements in HRQoL in adults and adolescents with TDT. These trials were registered at www.ClinicalTrials.gov as #NCT03655678 and #NCT04208529.
- Open Access
- 13 August 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (16) , 4126-4135
Allogeneic hematopoietic stem cell transplantation for STAT3 hyper-IgE syndrome: a worldwide study
Signal transduction and activator of transcription 3 hyperimmunoglobulin E syndrome (STAT3-HIES) is a multisystem disorder causing recurrent skin and respiratory infection with bronchiectasis, pneumatoceles, and aspergillosis; lymphoma; and extraimmune manifestations including fractures and vasculopathy. Published data on immune and extraimmune hematopoietic stem cell transplant (HSCT) outcomes focus on case reports or small cohorts. We conducted an international multicenter retrospective study of HSCT in STAT3-HIES. Primary end points were overall survival (OS) and event-free survival (EFS; events were death, graft failure, chronic graft-versus-host disease [GVHD]). We identified 41 patients over a 28-year period. HSCT indication was infection (93%) or lymphoma (7%). Median age at HSCT was 14 years (range, 4-45). Most patients had pre-HSCT respiratory disease (93%), including parenchymal lung disease (68%), and prior suspected/confirmed pulmonary fungal infection (32%). Patients received peripheral blood stem cells (51%) or marrow (49%) from HLA 10/10–matched unrelated donors (44%), matched family donors (44%), mismatched family donors (10%), or 1 9/10–mismatched unrelated donor (2%). Conditioning regimens were predominantly treosulfan-based (59%; with thiotepa, 34%); other patients received busulfan-based (24%) or melphalan-based (17%) regimens. Median follow-up for surviving patients was 5 years (0.8-28). The 5-year OS was 93%, and 5-year EFS 90%. Cumulative incidence of grade 2 to 4 acute GVHD was 22%. Median whole blood donor chimerism at latest follow-up was 100%. Eighty-seven percent of patients have reduced or no bacterial or fungal respiratory infection. After HSCT, 20% developed new skeletal fractures. This worldwide study expanded data on HSCT for STAT3-HIES to 41 patients; despite significant pre-HSCT pulmonary morbidity, OS was high, and patients have improved skin and respiratory disease though the impact on extraimmune manifestations appears limited.
- 13 August 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (16) , 4126-4135
Open AccessAllogeneic hematopoietic stem cell transplantation for STAT3 hyper-IgE syndrome: a worldwide study
Signal transduction and activator of transcription 3 hyperimmunoglobulin E syndrome (STAT3-HIES) is a multisystem disorder causing recurrent skin and respiratory infection with bronchiectasis, pneumatoceles, and aspergillosis; lymphoma; and extraimmune manifestations including fractures and vasculopathy. Published data on immune and extraimmune hematopoietic stem cell transplant (HSCT) outcomes focus on case reports or small cohorts. We conducted an international multicenter retrospective study of HSCT in STAT3-HIES. Primary end points were overall survival (OS) and event-free survival (EFS; events were death, graft failure, chronic graft-versus-host disease [GVHD]). We identified 41 patients over a 28-year period. HSCT indication was infection (93%) or lymphoma (7%). Median age at HSCT was 14 years (range, 4-45). Most patients had pre-HSCT respiratory disease (93%), including parenchymal lung disease (68%), and prior suspected/confirmed pulmonary fungal infection (32%). Patients received peripheral blood stem cells (51%) or marrow (49%) from HLA 10/10–matched unrelated donors (44%), matched family donors (44%), mismatched family donors (10%), or 1 9/10–mismatched unrelated donor (2%). Conditioning regimens were predominantly treosulfan-based (59%; with thiotepa, 34%); other patients received busulfan-based (24%) or melphalan-based (17%) regimens. Median follow-up for surviving patients was 5 years (0.8-28). The 5-year OS was 93%, and 5-year EFS 90%. Cumulative incidence of grade 2 to 4 acute GVHD was 22%. Median whole blood donor chimerism at latest follow-up was 100%. Eighty-seven percent of patients have reduced or no bacterial or fungal respiratory infection. After HSCT, 20% developed new skeletal fractures. This worldwide study expanded data on HSCT for STAT3-HIES to 41 patients; despite significant pre-HSCT pulmonary morbidity, OS was high, and patients have improved skin and respiratory disease though the impact on extraimmune manifestations appears limited.
- 18 July 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (3) , 323-333
Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT
Selecting the most suitable alternative donor becomes challenging in severe aplastic anemia (SAA) when a matched sibling donor (MSD) is unavailable. We compared outcomes in patients with SAA undergoing stem cell transplantation (SCT) from matched unrelated donors (MUD) (n = 1106), mismatched unrelated donors (MMUD) (n = 340), and haploidentical donors (Haplo) (n = 206) registered in the European Society for Blood and Marrow Transplantation database (2012-2021). For Haplo SCT, only those receiving posttransplant cyclophosphamide for graft-versus-host disease (GVHD) prophylaxis were included. Median age was 20 years, and the median time from diagnosis to transplantation 8.7 months. Compared with MUD, MMUD (hazard ratio [HR], 2.93; 95% confidence interval [CI], 1.52-5.6) and Haplo (HR, 5.15; 95% CI, 2.5-10.58) showed significantly higher risks of primary graft failure. MUD had lower rates of acute GVHD compared with MMUD and Haplo (grade 2-4: 13%, 22%, and 19%, respectively; P < .001; grade 3-4: 5%, 9%, and 7%, respectively; P = .028). The 3-year nonrelapse mortality rate was 14% for MUD, 19% for MMUD, and 27% for Haplo (P < .001), whereas overall survival and GVHD and relapse-free survival (GRFS) rates were 81% and 73% for MUD, 74% and 65% for MMUD, and 63% and 54% for Haplo, respectively (P < .001). In addition to donor type, multivariable analysis identified other factors associated with GRFS such as patient age, performance status, and interval between diagnosis and transplantation. For patients with SAA lacking an MSD, our findings support MUDs as the preferable alternative donor option. However, selecting between an MMUD and Haplo donor remains uncertain and requires further exploration.
- 18 July 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (3) , 323-333
Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT
Selecting the most suitable alternative donor becomes challenging in severe aplastic anemia (SAA) when a matched sibling donor (MSD) is unavailable. We compared outcomes in patients with SAA undergoing stem cell transplantation (SCT) from matched unrelated donors (MUD) (n = 1106), mismatched unrelated donors (MMUD) (n = 340), and haploidentical donors (Haplo) (n = 206) registered in the European Society for Blood and Marrow Transplantation database (2012-2021). For Haplo SCT, only those receiving posttransplant cyclophosphamide for graft-versus-host disease (GVHD) prophylaxis were included. Median age was 20 years, and the median time from diagnosis to transplantation 8.7 months. Compared with MUD, MMUD (hazard ratio [HR], 2.93; 95% confidence interval [CI], 1.52-5.6) and Haplo (HR, 5.15; 95% CI, 2.5-10.58) showed significantly higher risks of primary graft failure. MUD had lower rates of acute GVHD compared with MMUD and Haplo (grade 2-4: 13%, 22%, and 19%, respectively; P < .001; grade 3-4: 5%, 9%, and 7%, respectively; P = .028). The 3-year nonrelapse mortality rate was 14% for MUD, 19% for MMUD, and 27% for Haplo (P < .001), whereas overall survival and GVHD and relapse-free survival (GRFS) rates were 81% and 73% for MUD, 74% and 65% for MMUD, and 63% and 54% for Haplo, respectively (P < .001). In addition to donor type, multivariable analysis identified other factors associated with GRFS such as patient age, performance status, and interval between diagnosis and transplantation. For patients with SAA lacking an MSD, our findings support MUDs as the preferable alternative donor option. However, selecting between an MMUD and Haplo donor remains uncertain and requires further exploration.
- Open Access
- 26 June 2024
- Published by Association for Computing Machinery (ACM)
- p. 329-336
Exploring Machine Learning Applications for Biophilic Art Displays to Promote Health and Well-being
Research has shown that the use of biophilic elements in public or private spaces is effective in alleviating stress, improving mental well-being, and increasing innovativeness in the general public. Studies reveal that exposure to Biophilic art can improve an individual’s mental well-being. Many urban settings have few natural representations hence, the goal of our research is to use machine learning algorithms to develop a novel digital biophilic art categorization and display system to promote mental health and well-being. An initial survey conducted indicates a strong correlation between biophilia and positive emotions. We applied classification algorithms to develop an artwork recommendation system based on self-reported emotional responses to biophilic art pieces. Initial findings suggest a reduction in negative emotions and an increase in positive emotions, whilst using the system. This supports machine learning for the categorization and recommendation of biophilic art. It is in line with the importance of the integration of nature into built environments, and advocates the expansion of biophilic art databases, using more inclusive, emotionally responsive art recommendation systems.
- 26 June 2024
- Published by Association for Computing Machinery (ACM)
- p. 329-336
Open AccessExploring Machine Learning Applications for Biophilic Art Displays to Promote Health and Well-being
Research has shown that the use of biophilic elements in public or private spaces is effective in alleviating stress, improving mental well-being, and increasing innovativeness in the general public. Studies reveal that exposure to Biophilic art can improve an individual’s mental well-being. Many urban settings have few natural representations hence, the goal of our research is to use machine learning algorithms to develop a novel digital biophilic art categorization and display system to promote mental health and well-being. An initial survey conducted indicates a strong correlation between biophilia and positive emotions. We applied classification algorithms to develop an artwork recommendation system based on self-reported emotional responses to biophilic art pieces. Initial findings suggest a reduction in negative emotions and an increase in positive emotions, whilst using the system. This supports machine learning for the categorization and recommendation of biophilic art. It is in line with the importance of the integration of nature into built environments, and advocates the expansion of biophilic art databases, using more inclusive, emotionally responsive art recommendation systems.
- 5 January 2023
- Published by American Society of Hematology in Blood
- Vol. 141 (1) , 60-71
Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunity
Allogeneic hematopoietic stem cell transplantation (alloSCT) is curative for severe inborn errors of immunity (IEIs), with recent data suggesting alloSCT in adulthood is safe and effective in selected patients. However, questions remain regarding the indications for and optimal timing of transplant. We retrospectively compared outcomes of transplanted vs matched nontransplanted adults with severe IEIs. Seventy-nine patients (aged ≥ 15 years) underwent alloSCT between 2008 and 2018 for IEIs such as chronic granulomatous disease (n = 20) and various combined immune deficiencies (n = 59). A cohort of nontransplanted patients from the French Centre de Référence Déficits Immunitaires Héréditaires registry was identified blindly for case-control analysis, with ≤3 matched controls per index patient, without replacement. The nontransplanted patients were matched for birth decade, age at last review greater than index patient age at alloSCT, chronic granulomatous disease or combined immune deficiencies, and autoimmune/lymphoproliferative complications. A total of 281 patients were included (79 transplanted, 202 nontransplanted). Median age at transplant was 21 years. Transplant indications were mainly lymphoproliferative disease (n = 23) or colitis (n = 15). Median follow-up was 4.8 years (interquartile range, 2.5-7.2). One-year transplant-related mortality rate was 13%. Estimated disease-free survival at 5 years was higher in transplanted patients (58% vs 33%; P = .007). Nontransplanted patients had an ongoing risk of severe events, with an increased mean cumulative number of recurrent events compared with transplanted patients. Sensitivity analyses removing patients with common variable immune deficiency and their matched transplanted patients confirm these results. AlloSCT prevents progressive morbidity associated with IEIs in adults, which may outweigh the negative impact of transplant-related mortality.
- 5 January 2023
- Published by American Society of Hematology in Blood
- Vol. 141 (1) , 60-71
Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunity
Allogeneic hematopoietic stem cell transplantation (alloSCT) is curative for severe inborn errors of immunity (IEIs), with recent data suggesting alloSCT in adulthood is safe and effective in selected patients. However, questions remain regarding the indications for and optimal timing of transplant. We retrospectively compared outcomes of transplanted vs matched nontransplanted adults with severe IEIs. Seventy-nine patients (aged ≥ 15 years) underwent alloSCT between 2008 and 2018 for IEIs such as chronic granulomatous disease (n = 20) and various combined immune deficiencies (n = 59). A cohort of nontransplanted patients from the French Centre de Référence Déficits Immunitaires Héréditaires registry was identified blindly for case-control analysis, with ≤3 matched controls per index patient, without replacement. The nontransplanted patients were matched for birth decade, age at last review greater than index patient age at alloSCT, chronic granulomatous disease or combined immune deficiencies, and autoimmune/lymphoproliferative complications. A total of 281 patients were included (79 transplanted, 202 nontransplanted). Median age at transplant was 21 years. Transplant indications were mainly lymphoproliferative disease (n = 23) or colitis (n = 15). Median follow-up was 4.8 years (interquartile range, 2.5-7.2). One-year transplant-related mortality rate was 13%. Estimated disease-free survival at 5 years was higher in transplanted patients (58% vs 33%; P = .007). Nontransplanted patients had an ongoing risk of severe events, with an increased mean cumulative number of recurrent events compared with transplanted patients. Sensitivity analyses removing patients with common variable immune deficiency and their matched transplanted patients confirm these results. AlloSCT prevents progressive morbidity associated with IEIs in adults, which may outweigh the negative impact of transplant-related mortality.
- Open Access
- 16 August 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (16) , 4715-4718
CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy
Khushnuma Mullanfiroze, Arina Lazareva, Jan Chu, Lindsey Williams, Saskia Burridge, Juliana M Furtado Silva, Robert Chiesa, Kanchan Rao, Giovanna Lucchini, Sara
- 16 August 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (16) , 4715-4718
Open AccessCD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy
Khushnuma Mullanfiroze, Arina Lazareva, Jan Chu, Lindsey Williams, Saskia Burridge, Juliana M Furtado Silva, Robert Chiesa, Kanchan Rao, Giovanna Lucchini, Sara
- Open Access
- 9 November 2021
- Published by American Society of Hematology in Blood Advances
- Vol. 5 (21) , 4500-4503
Letermovir prophylaxis in T-cell–depleted transplants: breakthrough and rebound infections in the postmarketing setting
Maria A V Marzolini, Varun Mehra, Kirsty J Thomson, Eleni Tholouli, Adrian JC Bloor, Anne Parker, Richard Andrew Lovell, Kim Orchard, Amy Publicover, Emma Nicho
- 9 November 2021
- Published by American Society of Hematology in Blood Advances
- Vol. 5 (21) , 4500-4503
Open AccessLetermovir prophylaxis in T-cell–depleted transplants: breakthrough and rebound infections in the postmarketing setting
Maria A V Marzolini, Varun Mehra, Kirsty J Thomson, Eleni Tholouli, Adrian JC Bloor, Anne Parker, Richard Andrew Lovell, Kim Orchard, Amy Publicover, Emma Nicho